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Abstract: Immunization screening forms are completed for each patient that is to be vaccinated in the
pharmacy. Screening forms contain demographic and health questions, which are used to determine
if a patient is contraindicated to receive a vaccine. The objective is to determine if patient responses to
questions on these forms can be used to identify potential vaccine indications. De-identified data was
retrospectively collected from 11 community pharmacies in California and Michigan that included
basic demographics, answers to immunization screening questions, and vaccine(s) administered
during that visit. The Advisory Committee on Immunization Practices (ACIP) recommendations were
used to forecast vaccine needs using the limited demographic and health history available from the
screening forms. Descriptive statistics are presented, characterizing patient demographics and health
condition-based recommendations, and the percentage of patients in a pharmacy population that may
have potential indications for additional vaccines. Data were collected from 8669 pharmacy vaccine
screening forms. Using the patient’s date of birth on the screening form, 10% (n = 759) and 34.6%
(n = 2615) of patients receiving vaccines at the pharmacy may be indicated for the zoster, or both the
zoster and pneumococcal vaccines, respectively. Screening form questions that inquire about medical
history are also able to identify 13.9% (n = 977) of patients with a potential need for pneumococcal
vaccines. Our data indicate that pharmacists can identify potential immunization opportunities
proactively by using their immunization screening form, not only to identify contraindications,
but also indications.
Keywords: vaccines; pharmacy; screening; missed opportunities; indications

1. Introduction
One of the barriers to increasing adult vaccination rates and reasons for missed opportunities for
vaccination is that many healthcare professionals do not routinely assess their patient’s vaccination
status [1]. Pharmacists across the United States (U.S.) have been vaccinating since the 1990s. However,
pharmacists have traditionally been reactive vaccinators, waiting for patients to ask for a vaccine instead
of proactively assessing them for vaccine needs. Pharmacists may also only promote a subset of vaccines
that are commonly reimbursed for administration in the pharmacy by third party payers or prescription
drug plans (e.g., zoster and pneumococcal vaccines) [2]. The National Vaccine Advisory Committee
and the Centers for Disease Control and Prevention (CDC) advocate that all healthcare professionals
be proactive in assessing immunization and providing a “strong recommendation” to their patients
for needed vaccinations, as this is the strongest predictor of patients getting vaccinated [1,3]. Some
interventions to identify and reduce missed opportunities for vaccination that have been published
include education for patients and parents, electronic notices in the electronic medical records for
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providers, provider performance reports, patient outreach through postcards, phone calls and home
visits, and manual screening of all patients’ vaccination records [4].
In a pharmacy, before a vaccine is administered, a vaccine screening form is routinely completed
by all patients to identify contraindications to vaccination [5]. Screening forms contain demographic
and health questions and are traditionally used by healthcare providers to determine if a patient
is contraindicated to receive the requested vaccine. However, it is possible that a contraindication
to one vaccine may be an indication for another. For example, a patient who checked they were
immunocompromised would be contraindicated from receiving a live vaccine, but would likely
be indicated for the pneumococcal vaccines. In addition, even when the requested vaccine is not
contraindicated, the form may indicate there are still other vaccines that may be recommended for
the patient. A standardized vaccine screening checklist from the Immunization Action Coalition
(IAC) and endorsed by the CDC can be found here: http://www.immunize.org/catg.d/p4065.pdf
(Table 1) [6]. There are previous data on the successful use of proprietary forms developed by
individual pharmacies to screen and assess patients for vaccination needs; however, to our knowledge,
there are no published reports evaluating the use of standard CDC endorsed checklist questions on a
pharmacy-based vaccine screening form to not only identify contraindications to vaccination, but also
possible vaccination opportunities [7,8]. The CDC has developed additional tools, separate from the
screening questionnaire, to identify other indications, such as travel, health conditions, occupation,
and lifestyle for vaccinations [9,10].
Table 1. Immunization Action Coalition (IAC) and Centers for Disease Control and Prevention (CDC)
recommended questions when screening for vaccine contraindications and precautions.
Question Number

Question

1

Are you sick today?

2

Do you have allergies to medications, food, a vaccine component, or latex?

3

Have you ever had a serious reaction after receiving a vaccination?

4

Do you have a long-term health problem with heart disease, lung disease, asthma,
kidney disease, metabolic disease (e.g., diabetes), anemia, or other blood disorders?

5

Do you have cancer, leukemia, HIV/AIDS, or any other immune system problem?

6

In the past 3 months, have you taken medications that affect your immune system,
such as prednisone, other steroids, or anticancer drugs; drugs for the treatment of
rheumatoid arthritis, Crohn’s disease, or psoriasis; or have you had radiation
treatment?

7

Have you had a seizure or a brain or other nervous system problem?

8

During the past year, have you received a transfusion of blood or blood products, or
been given immune (gamma) globulin or an antiviral drug?

9

For women: Are you pregnant or is there a chance you could be pregnant during the
next month?

10

Have you received any vaccinations in the past 4 weeks?

These are the questions recommended by the IAC and the CDC to screen patients for precautions and contraindications
to vaccines, adopted into a table format [5].

We believe that vaccine screening forms can be used to identify potential opportunities to vaccinate
and make proactive vaccine recommendations based on a uniform set of questions to be answered for
every patient being vaccinated at the pharmacy. By retrospectively assessing the forms currently being
used in a variety of community pharmacy practice settings, we hope to (1) create a standard set of
recommendations based on questions on the screening form that are likely to yield a vaccine indication;
and (2) categorize potential opportunities for vaccination, within the population that receive vaccines
from the pharmacy, using the screening form questions.
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2. Materials and Methods
2.1. Data Source and Study Sample
This was a retrospective cross-sectional study evaluating one year of data from 11 community
pharmacies (6 in California [CA] and 5 in Michigan [MI]). These pharmacies were a convenience sample
of pharmacies that also participated as demonstration pharmacies for a more comprehensive American
Pharmacists Association/CDC project (Cooperative Agreement Number, IH23IP000984, funded by
the CDC) related to immunization registry reporting occurring concurrently with this study. The
participating pharmacies represent different areas of community pharmacy practice, including four
chain (stand alone, mass merchandiser, and grocery store) and seven independent pharmacies.
All completed vaccine screening forms from 1 June 2015 through 31 May 2016 were gathered
from each pharmacy and de-identified data were collected and analyzed using patients’ responses to
screening questions (Table 1) and demographic questions asked on the form. Data collected included
basic demographics, dichotomous answers to screening questions, and vaccine(s) administered during
that visit. Screening forms also serve as vaccine administration records, noting which vaccines were
administered during that visit. A comorbidity is considered an answer of “yes” to questions #4, #5, or
#6 in Table 1. Data were analyzed using descriptive statistics, and a comparison between the two states
was made using Fisher’s test with adjusted p-values using the Bonferroni correction. This study was
approved by the Institutional Review Board of Chapman University.
2.2. Determining Vaccine Indications from Screening Forms
The Advisory Committee on Immunization Practices (ACIP) immunization schedules available as
of May 2016 were used to forecast a vaccine needed using the demographic and screening question
responses available [11,12]. Only vaccine indications that correlated directly with demographic items
or questions on the screening forms were included in the final analysis.
3. Results
3.1. Study Population
There were a total of 8669 vaccine screening forms (or patient encounters) that represented 9804
administered vaccines, with 10.6% (n = 917) of patients receiving more than one vaccine at their visit to
the pharmacy (Table 2). The total number of vaccines administered by a single pharmacy over a 1-year
period varied from 101 to 2162 vaccines. The majority of the vaccinations that were administered by
the pharmacies were influenza vaccines (74.5%; n = 7307). The average age of the pharmacy vaccine
recipients was 53 years old (range <1–108 years old; median = 56), with 59.4% identifying as female.
Table 2. Patient encounter demographics.
N (%)

CA

MI

Patient encounters/screening forms

8669

3163 (36.5)

5506 (63.5)

Total number of vaccines administered

9804

3937 (41.8)

5867 (59.8)

Patient encounters receiving >1 vaccine

917 (10.6)

581 (63.4)

336 (36.6)

Average age (years) ˆ

52.8 ± 20.8
Median = 56

53.5

52.4

Patients with self-reported co-morbidities *

977 (13.9)

411 (42.1)

566 (57.9)

ˆ 7555 forms provided dates of birth or valid dates of birth. * Only 7018 forms asked about co-morbidities, indicating
% of those asked. CA, California; MI, Michigan.
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3.2. Frequency of CDC Recommended Questions Asked
Evaluation of the current use of screening forms by the 11 pharmacies in this project revealed that
7 of the 11 pharmacies asked all 10 of the CDC recommended vaccine screening questions on their
screening forms. All the chain (n = 2), mass merchandiser (n = 1), and grocery store (n = 1) pharmacies
in this study used all of the recommended CDC screening questions. The independent pharmacies
that did not use all the questions, used between 2 to 8 of the questions recommended by the IAC and
CDC. The one question that was used by all 11 pharmacies was related to inquiring about allergies
(question #2 on Table 1).
3.3. Potential Recommended Vaccinations Based on Vaccine Screening Form Responses
We identified that patients who receive vaccination from the pharmacy have at least one additional
vaccine, besides the influenza vaccine, that may be recommended for them based on their answers,
or demographic information, from the vaccine contraindication screening form. Using the age
(or date of birth) from the demographics section of the vaccine contraindication screening forms, one
can identify an indication for zoster, pneumococcal, meningococcal ACWY (MCV4), serogroup B
meningococcal (MenB), tetanus, diphtheria & acellular pertussis (Tdap), and human papillomavirus
(HPV9) vaccination (Table 3). We were able to identify that 10% (n = 759) and 34.6% (n = 2615) of
patients receiving vaccination(s) at the pharmacy may be indicated for the zoster, or both the zoster
and pneumococcal vaccines, respectively. Of the 2615 patients that may be indicated for the zoster
and pneumococcal vaccines, 952 (36.4%) patients received one or both of those vaccines during their
pharmacy vaccine encounter(s) within this study period (Tables 3 and 4).
Table 3. Possible recommended vaccinations based on vaccine screening form.
Fisher’s Test
Bonferroni
Adjusted
p-Value

Vaccine
Recommendation

440 (9.9)

p = 1.0

ZVL

Demographics

1160 (37.4)

1455 (32.7)

p = 0.04199

PCV13, PPSV23,
ZVL

Demographics

195 (2.6)

98 (3.2)

97 (2.2)

p = 0.14508

HPV, MCV4,
MenB, Tdap

Demographics

592 (7.8)

235 (7.6)

357 (8.0)

p = 1.0

HPV, MCV4,
MenB, Tdap

Demographics

Indication

N (%)

N (%) CA +

N (%) MI #

60–64 years ˆ

759 (10.0)

319 (10.3)

≥65 years ˆ

2615 (34.6)

11–21 (males) ˆ
11–26 (females) ˆ

Screening
Form Item

AGE

OTHER CONDITIONS
Patient with
comorbidities *

977 (13.9)

411 (13.2)

566 (12.7)

p = 1.0

PCV13, PPSV23

Questions:
#4, #5, #6

Pregnant women

41 (0.47)

11 (0.4)

30 (0.7)

p = 1.0

Tdap

Question: #9

ˆ 7555 forms provided dates of birth or valid dates of birth. * Only 7018 forms asked about co-morbidities, indicating
% of those asked. + 3103 forms in CA that provided dates of birth or valid dates of birth. # 4452 forms in MI that
provided dates of birth or valid dates of birth. Key: ZVL = zoster vaccine live; PCV13 = pneumococcal conjugate;
PPSV23 = pneumococcal polysaccharide; HPV = human papillomavirus; MenB = serogroup B meningococcal; Tdap
= tetanus, diphtheria & acellular pertussis; MCV4 = meningococcalACWY.

The screening forms that inquired about chronic conditions were able to identify the potential
need for pneumococcal vaccine in 13.9% (n = 977) of the study population. Within this number of
patients with chronic conditions that are risk factors for pneumococcal disease, 210 out of the 977
(21.5%) received a pneumococcal vaccine during their pharmacy vaccine encounter(s) within this study
period (Tables 3 and 4).
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A group of young males aged 11–21 years old (2.6%, n = 195) and females aged 11–26 years
old (7.8%, n = 592) were identified as patients who should be assessed for HPV9, MCV4, MenB,
and Tdap vaccination. We found that only 16.4% (n = 32) of the males and 15.9% (n = 94) of the females
indicated for vaccines received at least one of the recommended vaccines during their pharmacy
vaccine encounter within this study period (Tables 3 and 4). Pregnancy with no determination of
trimester was assessed on 10 of 11 pharmacy screening forms, which represented only 0.47% (n = 41)
of the study population. Of the 41 pregnant women, 9 (22%) received a Tdap vaccine during their
pharmacy vaccine encounter(s) within this study period.
Comparing CA and MI for possible recommended vaccinations based on vaccine screening form
questions, the only indication that was significantly different (p = 0.04199) between the populations was
for those adults ≥65 years of age in CA (Table 3). When testing for differences between the two states for
those who actually received any of the possibly recommended vaccines during their vaccine encounter
at the pharmacy, CA patients ≥65 years, females 11–26 years of age, and those with comorbidities were
significantly more likely to receive at least one of the potential vaccines indicated for them (Table 4).
Table 4. Patients that received any of the indicated vaccine(s) during their encounter.

Indication

Vaccine

N (%)

Total Patients
Receiving Either
Vaccine(s) during
Encounter N (%)

60–64 years ˆ

ZVL

759 (10.0)

≥65 years ˆ

PCV13,
PPSV23,
ZVL

11–21 (males) ˆ
11–26 (females) ˆ

N (%) CA

N (%) MI

Fisher’s Test
Bonferroni
Adjusted p-Value

148 (19.5)

72 (48.6)

76 (51.4)

p = 1.0

2615 (34.6)

952 (36.4)

533 (56.0)

419 (44.0)

p < 0.001

HPV, MCV4,
MenB, Tdap

195 (2.6)

32 (16.4)

20 (62.5)

12 (37.5)

p = 1.0

HPV, MCV4,
MenB, Tdap

592 (7.8)

94 (15.9)

77 (81.9)

17 (18.1)

p = 0.00534

AGE

OTHER CONDITIONS
Patient with
comorbidities *

PCV13,
PPSV23

977 (13.9)

210 (21.5)

113 (53.8)

97 (46.8)

p = 0.02587

Pregnant
women

Tdap

41 (0.47)

9 (22)

7 (77.8)

2 (22.2)

p = 0.08254

ˆ 7555 forms provided dates of birth or valid dates of birth. * Only 7018 forms asked about co-morbidities, indicating
% of those asked. Key: ZVL = zoster vaccine live; PCV13 = pneumococcal conjugate; PPSV23 = pneumococcal
polysaccharide; HPV = human papillomavirus; MenB = serogroup B meningococcal; Tdap = tetanus, diphtheria &
acellular pertussis; MCV4 = meningococcalACWY.

4. Discussion
Our study suggests that the vaccine indications that can be inferred from the vaccine
contraindication screening form answers were based mostly on the patient’s age, obtained from
the demographics section of the pharmacy screening form. For adults, these age-based vaccine
indications are for the two pneumococcal vaccines and the zoster vaccines. According to key findings
from the CDC’s 2015 Surveillance of Vaccination Coverage among Adult Populations in the United
States (U.S.), although there was modest gain in the coverage for pneumococcal and zoster vaccinations
compared to the previous year, the coverage is still low and many adults remain unvaccinated with
recommended vaccines [13]. In children and adolescents, the age-based vaccine indications that can be
inferred from the screening form responses are for the HPV9, MCV4, MenB, and Tdap vaccines. In 2016,
the CDC estimated that only 43.4% of teens had received the complete recommended HPV vaccination
series and that among teens aged 13–17 years, coverage with two or more MenACWY doses was
39.1% [14]. The CDC also recommends that clinicians consistently recommend and simultaneously
administer Tdap, MenACWY, and HPV vaccines at age 11–12 years as a method to increase coverage of
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these vaccines. In both California and Michigan, state law allows pharmacists to administer all adult
and adolescent vaccines without a prescription from a physician [15]. For example, when teens present
for influenza vaccination, reviewing the patient’s response to the vaccine contraindication screening
form allows identification of other vaccination needs to discuss with the patient and parent.
When looking at actual questions on the screening forms, we were able to identify that 4 out of
the 10 questions are likely to yield a vaccine recommendation. An answer of “yes” to three of these
questions (#4, #5, or #6) elicits the possible need for one, or both, of the pneumococcal vaccines (Table 1).
These questions ask about the presence of comorbidities such as chronic illnesses (chronic heart, liver,
kidney, lung, diabetes) and impaired immune function due to disease or medications. Although the
intention of these three questions is to avoid administering a live vaccine to patients with these risk
factors, the content of these three questions essentially also asks the patient to confirm if they have
factors that increase their risk for getting pneumococcal disease, and therefore should be recommended
pneumococcal vaccination. We were able to identify that 13.9% of our study sample with comorbidities
(i.e., answering “yes” to questions #4, #5, or #6) would be indicated for the pneumococcal vaccine.
However, in this high-risk group, national data suggest that only approximately 25% of adults less than
65 years of age with an indication for pneumococcal vaccination report ever having been vaccinated
with pneumococcal vaccine [13]. Using a patient’s response to the screening form questions that ask
about comorbidities can identify these patients that often go unvaccinated. Even the CDC states that
their screening questions are for precautions and contraindications to vaccines, not indications [6]. In
the pharmacies in our sample, only the screening form was used and not the CDC’s questionnaire to
determine the recommended vaccines. Thus a large opportunity to identify patients potentially in
need of recommended vaccines is lost.
The number of patients with comorbid conditions indicative of the need for immunization in our
study is likely an underestimation due to several possible screening form discrepancies: (1) At one
pharmacy, patients may have left the question blank because it asked it as a free-response question
instead of a yes/no; (2) at another pharmacy in our study sample, they did not ask about comorbidities at
all; and (3) some pharmacies had procedures that instructed patients not to complete the questions that
ask about comorbidities because they were there for an inactivated vaccine and having a comorbidity
would generally not be a contraindication to receiving inactivated vaccines. To increase the detection
of comorbidities, pharmacies can also use inferred diagnoses (i.e., using the medications a patient takes
to infer their diagnoses) from their pharmacy dispensing records. Obtaining an inferred diagnosis
for comorbidities was not possible in our sample as a current medication list was not included in the
pharmacy screening questionnaires.
The small number of pregnant women identified in our pharmacy population may be expected,
as the literature suggests that the majority of pregnant women tend to receive their Tdap (96%)
and influenza (97.3%) vaccine in a traditional healthcare setting, such as their OB/GYN or family
doctor [16,17]. However, pharmacists should still incorporate a vaccine needs assessment for pregnant
women, as the U.S. maternal vaccination rate with Tdap and influenza vaccines is suboptimal. During
the 2017–2018 influenza season, only 49.1% of pregnant women received influenza vaccination, 54.4%
with a live birth received Tdap during pregnancy, and 32.8% received both recommended vaccines [18].
Other vaccines may be indicated for patients of different ages, medical conditions, occupations, and
lifestyles, but it would require the pharmacist to elicit more information from the patient.
Adult vaccination rates are still below the Healthy People 2020 target goals, and pharmacy-based
immunization screening forms can identify opportunities to improve immunization rates. The zoster
vaccine goal is set very low at 30% compared to the other vaccines (e.g., 90% for pneumococcal), and
its coverage is currently only at 33.4% using the now non-preferred live zoster vaccine [19]. Using
pharmacy screening forms to infer indications for vaccinations is another method that can identify
patients who should be vaccinated to increase coverage from vaccine-preventable diseases and help
reach our Healthy People 2020 goals. The CDC and other organizations have developed additional tools
for screening, which may increase the chances of identifying missed vaccine opportunities, but may

Pharmacy 2019, 7, 160

7 of 9

also increase paperwork and workflow burden for pharmacists and patients [9,10,20]. The additional
CDC questionnaire asks about other risk factors, such as if they are a healthcare worker, a man who
has sex with men, a college student, homeless, are planning travel, etc. Since the majority of the
vaccinations that were administered by the pharmacies were influenza vaccines (74.5%), and influenza
is recommended for everyone 6 months and older, this increases the pharmacists’ potential to identify
and make recommendations on other vaccine needs on, at least, an annual basis.
Across the board for all vaccines that were identified as potentially indicated, only 20–37% of
those indicated for the vaccine received that recommended vaccine during the pharmacy encounter
(Table 4). These results indicate that possibly 63–80% of the potential vaccine opportunities that are
identified using the screening form are true opportunities for the pharmacist to initiate a conversation
with the patient to assess for other needed vaccines.
While the age and pregnancy status of patients in CA and MI were similar, we did note a
statistically significantly greater percentage of the sample in CA being 65 years or older compared to
MI. This project, however, was not designed to detect and determine the reason for differences in the
populations vaccinated between the two states.
Published studies have centered on the success pharmacists have had in targeted vaccine
interventions to improve immunization rates, but all patients who come in for any vaccinations
should be screened for all additional vaccine needs [21–25]. Knowing the potential opportunities for
vaccination allows for the pharmacist or provider to directly assess the status of that specific vaccine
with the patient through open conversation or review of their records. A limitation of this study is that
the patients included in this study were from a convenience sample of eleven pharmacies limited to
Southern California and Michigan who agreed to participate. However, both chain and independent
pharmacies were included. In addition, the screening forms used by the chain pharmacies in this
project represent at least 13,378 pharmacies that use these forms across the United States, amplifying
the impact of this opportunity.
5. Conclusions
Our data indicate that pharmacists can identify potential immunization opportunities proactively
by using their current vaccine contraindication screening form. Age and comorbid conditions are
routinely collected by pharmacy-based immunization programs, but not all are using them the
same way, and none in this sample were actively using them to discover indications for vaccination.
Additionally, several occupational and lifestyle questions are missing from the pharmacy screening
form that are included in the CDC questionnaire. Therefore, all pharmacies should use the standard
CDC screening questions, as well as the questionnaire, and ensure all questions are filled out completely
by the patient so that any vaccination recommendations can be communicated to the patient at the same
time. Pharmacies should also use their immunization information system and pharmacy dispensing
system to proactively identify patients for vaccination. This leads to the identification of missed
vaccination opportunities, which may decrease the need for multiple visits, assist with follow-up,
and increase vaccine rates.
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